Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

(WHTM) — A global campaign is marking Brain Awareness Week through Sunday, and Penn State professors are explaining some of ...

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and ...